Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1 Expression”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT02453984
What this trial is testing

MPDL3280A-imaging-IST-UMCG

Who this might be right for
Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression
University Medical Center Groningen 45
Testing effectiveness (Phase 2)Study completedNCT04108026
What this trial is testing

Immunotherapy in Patient With Poor General Condition

Who this might be right for
Non-small Cell Lung Cancer Stage IV
Intergroupe Francophone de Cancerologie Thoracique 50
Large-scale testing (Phase 3)Active Not RecruitingNCT04547504
What this trial is testing

PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

Who this might be right for
Non-small-cell Lung Cancer
University Hospital, Brest 349
Early research (Phase 1)Study completedNCT06354387
What this trial is testing

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Who this might be right for
Hepatocellular Carcinoma
China Medical University Hospital 5
Not applicableNot Yet RecruitingNCT07331701
What this trial is testing

Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study

Who this might be right for
Lung NeoplasmsTumor Immune Microenvironment
Seoul National University Hospital 60
Not applicableLooking for participantsNCT05878977
What this trial is testing

Biomarkers in Immunotherapy of Melanoma

Who this might be right for
Metastatic MelanomaImmune Checkpoints InhibitorsGastrointestinal Microbiome (Bacterial and Viral)+1 more
Institute of Oncology Ljubljana 150
Large-scale testing (Phase 3)Looking for participantsNCT06357533
What this trial is testing

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 675
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05280626
What this trial is testing

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Who this might be right for
Diffuse Large B-Cell Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 100
Large-scale testing (Phase 3)Study completedNCT03933449
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study

Who this might be right for
Esophageal CarcinomaEsophagogastric Junction Carcinoma
Merck Sharp & Dohme LLC 123
Not applicableUnknownNCT02758314
What this trial is testing

Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients

Who this might be right for
Non-Small Cell Lung Cancer
Instituto Nacional de Cancerologia de Mexico 150
Not applicableLooking for participantsNCT06804135
What this trial is testing

Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer

Who this might be right for
Cervical Carcinoma
Tata Memorial Hospital 110
Not applicableStudy completedNCT01976884
What this trial is testing

Expression and the Clinical Significance of Neutrophil PD-L1 During Sepsis

Who this might be right for
SepsisImmunosuppression
Changhai Hospital 71
Not applicableUnknownNCT04892381
What this trial is testing

Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study

Who this might be right for
Lichen Planus
Cairo University 60
Not applicableLooking for participantsNCT07109154
What this trial is testing

DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

Who this might be right for
Lung Neoplasms
AstraZeneca 200
Large-scale testing (Phase 3)Looking for participantsNCT05919030
What this trial is testing

Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
Renmin Hospital of Wuhan University 155
Not applicableUnknownNCT04528940
What this trial is testing

Tumor Grade Determines PD-1/PDL-1 Expression

Who this might be right for
Endometrial CancerOvarian Cancer
RWJ Barnabas Health at Jersey City Medical Center 100
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06690216
What this trial is testing

Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors

Who this might be right for
Glioblastoma (GBM)Head and Neck Squamous Cell CarcinomaNon-Small Cell Lung Cancer+1 more
Man Hu 100
Not applicableStudy completedNCT04726735
What this trial is testing

Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer

Who this might be right for
Bladder Cancer
University Hospital, Bordeaux 100
Testing effectiveness (Phase 2)Study completedNCT03707587
What this trial is testing

M7824 in People With Recurrent Respiratory Papillomatosis

Who this might be right for
Recurrent Respiratory PapillomatosisRespiratory PapillomatosisLaryngeal Papilloma, Recurrent+1 more
National Cancer Institute (NCI) 9
Large-scale testing (Phase 3)Study completedNCT02564263
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)

Who this might be right for
Esophageal CarcinomaEsophagogastric Junction Carcinoma
Merck Sharp & Dohme LLC 628
Next Page